game on

Sports tech scale-up program launches in Houston, names inaugural cohort

Calling all sports tech startups ready to scale. Photo via Getty Images

Familiar names within Houston innovation have teamed up to launch a program for sports tech startups ready to scale.

Pokatok Labs announced five companies that make up its inaugural cohort. Pokatok is founded by Lawson Gow, founder of The Cannon; Chris Buckner, founder of Mainline; and Alex Gras, former chief commercial officer of The Cannon. (Note: Lawson Gow is the son of David Gow, the CEO of InnovationMap's parent company, Gow Media.)

The new program is targeting growing seed and series A startups across the scope of sports technology — health tech, gaming, fan experience, and more. The nine-week program is free to its cohort member and will run twice a year. Participating companies receive access to a network of organizations, advisors, investors, and subject matter experts within sports tech.

“Houston has a huge potential to emerge as a global leader in sports innovation, and the launch of this program is an important step in that direction,” says Gow, who serves as Pokatok's CEO.

The program will be housed in The Cannon Sports in 53West, which opened last year. Kate Evinger, who previously oversaw gBETA Houston's early stage accelerator, will lead Pokatok Labs as director.

“Each of the five companies are true disruptors within the global sports community. It is a privilege and an honor to be working alongside them, and we look forward to the great things to come from each '' Evinger says.

The first cohort of startups includes:

  • Detroit, Michigan-based Miro AI builds cutting-edge computer vision that analyzes images and videos to unlock athlete data. The technology has analyzed over 50 million athletes.
  • Monarc, headquartered in Dallas, has created a robotic quarterback called the Seeker. Several universities — like West Virginia University, Louisiana State University, and Washington University — have already tapped into the technology, as well as NFL professionals, including George Kittle, James White and Adrian Amos.
  • RE Cooling Tech, based in Lafayette, Louisiana, has a technology that cools and increases the performance of athletes before, during, and after physical exertion. The technology was validated in a study with The Korey Stringer Institute at the University of Connecticut showing efficacy in cooling and increased athletic performance.
  • Founded at MIT, Perch uses computer vision and machine learning to seamlessly track exercise, provide real time feedback, facilitate new types of competitions, and store the data for later analysis and progress tracking. The company has sold to more than 10 NFL teams, supporting two national championship college football teams, as well as a growing number of professional sports teams, colleges, military, high schools, performance facilities, and even individual home gyms.
  • Pennsylvania-based Reflexion is a portable neuro training service that gives athletes an edge with interactive lightboard based drills. Reflexion has raised over $4 million in venture funding to date, is used by thousands of athletes in homes and training centers, and is trusted by the likes of Under Armour, the Canadian National Soccer Team, and the Denver Nuggets.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted